Methylprednisolone — Drug Intelligence | 62 EU Trials

Filter these 62 trials by condition, phase, country and more.

Open in Search →

62 Registered trials

26 Recruiting

28 Completed trials

38 Sponsors

27 Countries

Phase III

Phase II

Phase III: 32 Phase II: 20 Phase I/II: 4 Phase IV: 4 Phase I: 1 Phase I (FiH): 1

Oversight events:

2 serious breaches 41 temporary halts 6 urgent safety measures 4 unexpected events 3 corrective measures across 17 trials

View oversight register →

Indications tested

Multiple sclerosis 5 Relapsing multiple sclerosis 3 Relapsing-remitting multiple sclerosis 3 Chronic graft versus host disease 2 Polymyositis 2 Multiple sclerosis relapse 2 Dermatomyositis 2 Injection site pain 1 Meniere's disease 1 Myelin oligodendrocyte glycoprotein antibody-associated disease 1 Primary myelofibrosis 1 Vertigo 1

Sponsors using this IMP

Assistance Publique Hopitaux De Paris 7 F. Hoffmann-La Roche AG 6 Kite Pharma Inc. 6 Charite Universitaetsmedizin Berlin KöR 2 Hansa Biopharma AB 2 Incyte Corp. 2 Pfizer Inc. 2 Prevail Therapeutics Inc. 2 Rigshospitalet 2 Tg Therapeutics Inc. 2 Tiohundra AB 2 Argenx 1

All trials

62 total

Pulse corticosteroids or/and Immunoglobulins to treat fulminant Myocarditis: a double-blind randomized controlled adaptive trial (The CORIUM… Pending

2023-506599-28-01 Phase II 1 country Assistance Publique Hopitaux De Paris
Corticoid Therapy in Acute Myocarditis Pending

2024-510602-90-00 Phase III 1 country Assistance Publique Hopitaux De Paris
The effect of corticosteroids on early recovery after major surgery in eldery patients: CORTERAS study Pending

2024-517602-28-00 Phase IV 1 country Ziekenhuis Oost Limburg
MULTICENTER, RANDOMIZED STUDY TO EVALUATE THE EFFICACY OF INDIVIDUALIZATION OF IMMUNOLOGICAL RISK BASED ON SELECTIVE BIOMARKERS (HLA EPLE… Pending

2025-520884-42-00 Phase IV 1 country Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
Rituximab as therapy for autoantibody mediated fibromyalgia (RAFT) - proof of concept Pending

2025-523465-21-00 Phase III 1 country Region Stockholm – SLSO
C0251006 - A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN … Recruiting

2022-502739-20-00 Phase III 10 countries Pfizer Inc.
Phase III clinical trial of ABCB5+ MSCs for the treatment of EB Recruiting

2022-500266-10-00 Phase III 12 countries Rheacell GmbH & Co. KG
Desensitisation with imlifidase prior to kidney transplant in highly sensitised children Recruiting

2022-500230-28-00 Phase II 4 countries Hansa Biopharma AB
Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting

2022-502503-30-00 Phase III 19 countries Princess Maxima Center For Pediatric Oncology
Steroid treatment in patients with heart attack - PULSE-MI 2 Recruiting

2025-524320-21-00 Phase III 1 country Rigshospitalet
Efficacy of methylprednisolone pulses in neuroendocrine cells hyperplasia of infancy: an early phase study (CORTICONEHI). Recruiting

2023-508132-65-00 Phase II 1 country Assistance Publique Hopitaux De Paris
metastatic colorectal cancer Recruiting

2023-504831-42-00 Phase III 1 country Assistance Publique Hopitaux De Paris
Immediate versus delayed treatment with azathioprine or rituximab in anti-myelin oligodendrocytes glycoprotein (anti-MOG) antibodies associa… Recruiting

2024-516243-81-00 Phase III 1 country Assistance Publique Hopitaux De Paris
Evaluating safety, efficacy and pharmacokinetics of a modified regimen of ublituximab (ENHANCE) Recruiting

2024-519284-18-00 Phase III 1 country Tg Therapeutics Inc.
An open-label extension study with dazukibart for participants with idiopathic inflammatory myopathies (including DM or PM) who have complet… Recruiting

2024-514648-10-00 Phase III 6 countries Pfizer Inc.
A randomized trial comparing efficacy and safety of etanercept and methotrexate in giant cell arteritis (EFFECTA) Recruiting

2023-506623-29-01 Phase II 1 country Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab (INCA034176) and Corticosteroids as Initial Treatment for Chroni… Recruiting

2023-510292-65-00 Phase III 8 countries Incyte Corp.
A Phase-2b, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-NMDA Receptor Enc… Recruiting

2023-504686-23-00 Phase II 2 countries Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Evaluation of the efficacy of Sphenopalatine Ganglion Block compared to Scalp Block in Supratentorial Intracranial Surgery : a Non-inferiori… Recruiting

2024-512112-22-01 Phase IV 1 country Centre hospitalier universitaire de Liege
Prospective comparison of sirolimus against corticosteroids in treatment of patients with active thyroid eye disease Recruiting

2023-510166-27-01 Phase III 1 country Helse Bergen HF
A clinical trial applying Regulatory T cells in kidney transplant recipients to investigate the safety and tolerability as an adjunctive the… Recruiting

2024-514398-23-00 Phase I/II 1 country Charite Universitaetsmedizin Berlin KöR
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting

2023-505436-35-00 Phase III 6 countries Lysarc
A multicenter randomized trial to evaluate the efficacy of pioglitazone to improve renal outcome in ANCA-associated vasculitis - RENATO Recruiting

2022-501057-36-00 Phase III 1 country Assistance Publique Hopitaux De Paris
Evaluation of the postoperative analgesic efficacy of erector spinae plane block in lumbar spinal surgery: a prospective randomized double-b… Recruiting

2023-504204-28-00 Phase IV 1 country CHU De Liege

Showing 1–24 of 62 trials

← All drugs A–Z